IMPAACT Studies in Development

The study you are looking for is in protocol development.

As the study protocol reaches Version 1.0, a study page will be developed.

  Study Number
(DAIDS ID)
Study Title Status

IMPAACT 2021

(38530)

Randomized Phase IB Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

In Development

IMPAACT 2019

(38504)

Phase I/II study of the pharmacokinetics, safety, and tolerability of dolutegravir/lamivudine/abacavir (Triumeq®) in HIV-1-infected children less than 12 years of age

In Development

IMPAACT 2020

(38505)

Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-center Trial

In Development

IMPAACT 2016

(38506)

Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence in Adolescents Living with HIV in Low Resource Settings

In Development

IMPAACT 2003B

(12041)

(Phoenix) Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients

In Development


Return to the full list of studies

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.